一种与鲁索替尼（一种新型 JAK1、2 抑制剂）相关的机会性感染。
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
机构信息
Department of Internal Medicine, Oregon Health and Science University, Portland, OR.
Department of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR.
出版信息
Chest. 2013 May;143(5):1478-1479. doi: 10.1378/chest.12-1604.
Abstract
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.
摘要
我们报告了一例接受鲁索替尼（一种用于治疗骨髓纤维化的 Janus 激酶 1、2 抑制剂）治疗的患者发生新型隐球菌肺炎的病例。我们推测，鲁索替尼通过对细胞介导免疫的影响导致了这种感染。临床医生应该意识到与这种新型药物类别相关的细胞内或机会性感染的潜在风险。
相似文献
1
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.一种与鲁索替尼（一种新型 JAK1、2 抑制剂）相关的机会性感染。
Chest. 2013 May;143(5):1478-1479. doi: 10.1378/chest.12-1604.
2
Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.接受鲁索替尼治疗的患者中出现隐球菌血症和嗜血分枝杆菌蜂窝织炎：病例报告及文献复习。
BMC Infect Dis. 2021 Jan 7;21(1):27. doi: 10.1186/s12879-020-05703-2.
3
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.芦可替尼：一种新型 JAK1/2 抑制剂，为骨髓纤维化的治疗提供了有前景的选择。
Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.
4
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
5
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
6
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
7
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
8
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.芦可替尼：一种用于治疗骨髓纤维化的口服 Janus 激酶 1 和 Janus 激酶 2 抑制剂。
Postgrad Med. 2013 Jan;125(1):128-35. doi: 10.3810/pgm.2013.01.2628.
9
Ruxolitinib.芦可替尼
Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16.
10
Ruxolitinib: a review of its use in patients with myelofibrosis.芦可替尼：在骨髓纤维化患者中的应用评价。
Drugs. 2015 Feb;75(3):297-308. doi: 10.1007/s40265-015-0351-8.
引用本文的文献
1
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.芦可替尼治疗的骨髓纤维化患者血细胞减少和感染的真实世界管理
EJHaem. 2025 Mar 21;6(2):e70007. doi: 10.1002/jha2.70007. eCollection 2025 Apr.
2
Cryptococcosis Associated With Biologic Therapy: A Narrative Review.生物治疗相关的隐球菌病：一篇叙述性综述。
Open Forum Infect Dis. 2024 Jun 26;11(7):ofae316. doi: 10.1093/ofid/ofae316. eCollection 2024 Jul.
3
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.鲁索替尼治疗的骨髓纤维化患者发生播散性组织胞浆菌病：一例报告及鲁索替尼相关侵袭性真菌感染的文献综述
J Fungi (Basel). 2024 Mar 31;10(4):264. doi: 10.3390/jof10040264.
4
Integrated Stress Response (ISR) Pathway: Unraveling Its Role in Cellular Senescence.整合应激反应（ISR）通路：揭示其在细胞衰老中的作用。
Int J Mol Sci. 2023 Dec 13;24(24):17423. doi: 10.3390/ijms242417423.
5
Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability.芦可替尼可抑制人肺巨噬细胞产生细胞因子，而不损害其吞噬能力。
Front Pharmacol. 2022 Aug 19;13:896167. doi: 10.3389/fphar.2022.896167. eCollection 2022.
6
Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review.芦可替尼治疗原发性骨髓纤维化合并隐球菌感染：一例报告及文献复习
Clin Case Rep. 2022 Feb 20;10(2):e05461. doi: 10.1002/ccr3.5461. eCollection 2022 Feb.
7
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.血液系统恶性肿瘤中的侵袭性真菌感染与靶向治疗
J Fungi (Basel). 2021 Dec 10;7(12):1058. doi: 10.3390/jof7121058.
8
Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report.类风湿关节炎中与JAK抑制剂治疗相关的肺结节：一例报告
Afr J Thorac Crit Care Med. 2021 Oct 4;27(3). doi: 10.7196/AJTCCM.2021.v27i3.116. eCollection 2021.
9
Adverse Effects of Immunosuppression: Infections.免疫抑制的不良反应：感染。
Handb Exp Pharmacol. 2022;272:287-314. doi: 10.1007/164_2021_550.
10
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.新冠疫情期间的费城染色体阴性慢性骨髓增殖性肿瘤：挑战与未来展望
Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.
本文引用的文献
1
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.托法替布，一种口服的 Janus 激酶抑制剂，用于治疗活动期溃疡性结肠炎。
N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.
2
Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.骨髓增殖性肿瘤的JAK抑制剂治疗面临的挑战。
N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119.
3
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
4
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.辉瑞公司的JAK抑制剂在类风湿性关节炎的3期试验中顺利通过。
Nat Biotechnol. 2011 Jun 7;29(6):467-8. doi: 10.1038/nbt0611-467.
5
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.报告至为期 3 年的前瞻性法国 RATIO 注册研究的接受抗 TNF 治疗患者的非结核性机会性感染的药物特异性风险。
Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.
6
Cryptococcal interactions with the host immune system.新型隐球菌与宿主免疫系统的相互作用。
Eukaryot Cell. 2010 Jun;9(6):835-46. doi: 10.1128/EC.00039-10. Epub 2010 Apr 9.
Zotero 插件